Summary of MOVENTIG (naloxegol) – Grunenthal Meds Hub

MANAGING OPIOID-INDUCED CONSTIPATION WITH A PERIPHERALLY TARGETED THERAPY

USE MOVENTIG (NALOXEGOL) IN ADULT PATIENTS WITH ONGOING OIC SYMPTOMS OF AT LEAST MODERATE SEVERITY DESPITE 4 DAYS OF LAXATIVE TREATMENT, WITHIN THE PRIOR 2 WEEKS¹

MOVENTIG is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).¹

An inadequate response to laxative(s) is defined by concurrent OIC symptoms of at least moderate severity whilst taking at least one laxative class for a minimum of four days in the prior 2 weeks.¹

MOVENTIG may be used with or without laxatives. MOVENTIG treatment must be withdrawn when systemic opioid therapy is stopped.¹

Click here for Prescribing Information.

Adverse Events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk/. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com

The recommended dose of MOVENTIG is 25 mg once daily. For patients with moderate or severe renal insufficiency, or patients taking moderate CYP3A4 inhibitors (e.g. diltiazem, verapamil), the starting dose of MOVENTIG is 12.5 mg. This can be increased to 25 mg if 12.5 mg is tolerated.¹

No dose adjustment is required for patients with cancer-related pain.¹ For full information on dosing, including use in special populations, please refer to the SmPC

MOVENTIG 25 mg ONCE DAILY:

Is a peripherally targeted therapy, indicated for the treatment of OIC in adults with symptoms of at least moderate severity while taking at least one laxative for a minimum of four days, in the prior 2 weeks¹

MOVENTIG, a peripherally acting mu-opioid antagonist (PAMORA), targets the cause of OIC, unlike laxatives.^1,2 Find out more About PAMORAs
Is supported by real-world evidence in cancer pain patients with OIC^3-5
Does not impact opioid-mediated analgesic effects on the central nervous system in patients with an intact blood-brain barrier¹

Find out more about MOVENTIG’s Efficacy
May be used with or without laxatives. MOVENTIG treatment must be withdrawn when systemic opioid therapy is stopped.¹ Find out more about How to Prescribe

Contraindications

MOVENTIG is contraindicated in the following:¹

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the SmPC, or any other opioid antagonist
Patients with known or suspected gastrointestinal (GI) obstruction or in patients at increased risk of recurrent obstructions, due to the potential for GI perforation
Patients with underlying malignancies of the GI tract or peritoneum; recurrent or advanced ovarian cancer; those on vascular endothelial growth factor (VEGF) inhibitor treatment
Concomitant use with strong CYP3A4 inhibitors (e.g. clarithromycin, ketoconazole, itraconazole or telithromycin; protease inhibitors such as ritonavir, indinavir or saquinavir; grapefruit juice when consumed in large quantities)

For full information on adverse events, special warnings and precautions for use, please refer to the SmPC

For advice on the responsible use of opioids to treat pain, please click here

How useful was this page to you?

Average:

References

1. MOVENTIG^® (naloxegol) Summary of Product Characteristics.

2. Leppert W. Adv Ther. 2010;27(10):714–730.

3. Cobo Dols M, et al. BMJ Support Palliat Care. 2021;0:1–9.

4. Lemaire A, et al. Support Care Cancer. 2021;29(12):7577–7586.

5. Davies A, et al. Cancers. 2022;14(5):1128.

M-MOV-UK-02-24-0005 July 2025

Europe

MOVENTIG 25 mg ONCE DAILY:

Contraindications